Treatment of metastatic melanoma has long been a challenge because of its resistance to traditional chemotherapeutics, leading to the search for alternative strategies. Aurora kinases are key mitotic regulators that are frequently overexpressed in various cancers including melanoma, making them ideal targets for drug development. Several Aurora kinase inhibitors have been developed and tested preclinically and clinically. PHA-739358 is currently one of the most advanced clinical compounds being tested in phase II clinical trials; however, its antitumor effect has not been tested in melanoma. In this study, the antiproliferative and anti-invasive effects of PHA-739358 were investigated in melanoma cell lines. The results demonstrated that PHA-739358 produces a time-dependent and dose-dependent inhibition of cell proliferation, induction of apoptosis, and inhibition of cell migration. Downregulation of matrix metalloproteinase-2 by the inhibition of NFjB-signaling pathway may contribute to PHA-739358-induced inhibition of migration. Furthermore, PHA-739358 enhanced temozolomide and Plx4032-induced apoptosis. This study suggests that Aurora kinase inhibitors may provide a new strategy for the treatment of advanced melanoma.
Introduction
Melanoma is the least common but the most deadly form of skin cancer, and is highly invasive and markedly resistant to conventional therapy. It has been estimated that there will be 76 250 new cases of invasive melanoma and 9180 deaths from melanoma in the USA in 2012 [1] . Melanoma is easily curable by surgical excision when detected early, but it is nearly incurable when discovered in its later stages, owing to both initial and rapidly acquired resistance to treatment. The 5-year survival rate for metastatic melanoma is dismal, ranging from 5 to 10% with a median survival rate of less than 8 months with treatment [2] . Standard therapy with agents such as dacarbazine, temozolomide (TMZ), and interleukin 2 is associated with notoriously low response rates (reviewed in Guida et al. [3] ). Therefore, there is an urgent need for the identification of novel agents for this deadly disease.
Recent progress in understanding the molecular mechanisms involved in the initiation and progression of melanoma has created new opportunities for developing novel therapeutic modalities. The discovery of BRAF mutations in melanoma created the first opportunity to develop oncogene-directed therapy in this disease and led to the development of compounds that inhibit aberrant BRAF activity. A decade later, vemurafenib, an orally available and well-tolerated selective BRAF V600E inhibitor, ushered in a new era of molecular treatments for advanced disease [4, 5] . Additional targets have been identified, and novel agents that impact on various signaling pathways or modulate the immune system hold the promise of a whole new therapeutic landscape for patients with metastatic melanoma (reviewed in Monzon and Dancey [6] ). Of the drugs tested to date in patients with metastatic melanoma, those that have yielded the best results are BRAF V600E inhibitors in melanomas carrying the V600E mutation [5] ; c-kit tyrosine kinase inhibitors in melanomas carrying c-kit mutations; and anticytotoxic T lymphocyte antigen 4 antibodies, which block the mechanisms involved in immune tolerance [7] . However, the rapid development of resistance to BRAF and c-kit inhibitors and the lack of biomarkers that predict treatment response in the case of anticytotoxic T lymphocyte antigen 4 blockers are significant clinical problems, emphasizing the need for additional and/or alternative treatment strategies [6, 8] .
Mitosis is a critical step in the proliferation of cancer cells and involves many redundant checkpoint systems controlling key steps of the process. Drugs that interfere with the normal progression of mitosis belong to the most successful cytotoxic agents currently used for anticancer therapy. The family of Aurora kinases (including members A, B, and C) plays an important role in maintaining the fidelity of mitosis, making them attractive novel targets for anticancer treatment [9] .
Aurora kinases are frequently overexpressed in various human cancers including cutaneous melanoma [10, 11] . Both Aurora kinases A and B have been shown to be upregulated in melanoma [10] . Furthermore their levels correspond to progression, increasing from in situ to primary and metastatic melanoma [10] . Their fundamental role in cell cycle regulation and observed aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Aurora kinase inhibitors (AKIs) are new mitosis-targeting drugs currently in clinical trials for the treatment of hematological and solid malignancies, including advanced melanoma (http://www.clinicaltrials. gov). Currently, there are about 30 AKIs in different stages of preclinical and clinical development. Several of them, such as VE-465, ENMD-2076, and PF-03814735, have been tested in preclinical melanoma models [10] [11] [12] and suggested promising antimelanoma effects. More importantly, Aurora B has been confirmed as a potential target in Plx4032-resistant (BRAF V600E inhibitor) melanoma cells [13] . Additionally, it has been shown that resistance to BRAF(V600E) inhibitor therapy is associated with reactivation of the mitogen-activated protein kinase pathway, and that Aurora B is a downstream target of mitogen-activated protein kinase signaling [13] , which may explain why Aurora B inhibition is effective in BRAF inhibitor-resistant cell lines.
PHA-739358 is one of the most advanced clinical compounds that are currently being tested in phase II clinical trials [14] (http://www.clinicaltrials.gov). PHA-739358 potently inhibits all Aurora kinase family members (A, B, and C), with a dominant inhibition of Aurora kinase B [15] . PHA-739358 is one of the first AKIs to enter the clinic and has been studied in phase I and II trials, showing therapeutic potential in anticancer therapy in a wide range of cancers, including both advanced solid tumors and leukemia [15, 16] . The clinical activity of PHA-739358 has largely been consistent with cytostatic effects, with the best response so far being stable disease in about 23.7% of evaluable patients with advanced or metastatic solid tumors [17] . However, the effect of PHA-739358 on melanoma has not yet been clinically tested. In this study, we investigated the antiproliferative and anti-invasive effects of PHA-739358 on melanoma in vitro. In addition, the potential of combination therapy of TMZ or Plx4032 with PHA-739358 for melanoma treatment was also examined.
Materials and methods

Chemicals and reagents
PHA-739358 and Plx4032 were purchased from Selleck Chemicals (Houston, Texas, USA). TMZ and MG132 were purchased from Sigma-Aldrich (St Louis, Missouri, USA). NFkB-P65 siRNA (Hs_RELA_5) (targeted sequence: 5 0 -AAGATCAATGGCTACACAGGA-3 0 ; sense strand: 5 0 -GAUCAAUGGCUACACAGGATT-3 0 ; antisense strand: 5 0 -UCCUGUGUAGCCAUUGAUCTT-3 0 ) was purchased from Qiagen (Valencia, California, USA). siLentFect transfection reagent was purchased from Bio-Rad (Hercules, California, USA).
Cell culture
Normal human melanocytes were isolated from discarded new-born foreskin and cultured in MCDB153 medium (Sigma-Aldrich) containing 2% fetal bovine serum (FBS), 0.3% bovine pituitary extract (Cambrex, Walkersville, Maryland, USA), 10 ng/ml TPA, 2 mmol/l CaCl 2 , 5 mg/ml insulin, and 0.1 mmol/l IBMX (Sigma-Aldrich) [18] . Immortalized human melanocytes (Mel-ST cells) (provided by Dr Robert A Weinberg, Cambridge, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 5% (V/V) FBS, 5% (V/V) newborn bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Carlsbad, California, USA). Immortalized human melanocytes (PIG1 cells) (provided by Dr Caroline Le Poole, Loyola University, Chicago, Illinois, USA) were cultured in Cascade Biologics Medium 254 supplemented with 1% HGMS (containing BPE, FBS, bovine insulin, bovine transferring, bFGF, hydrocortisone, heparin and PMA) (Cascade Biologics, Portland, Oregon, USA). Melanoma cell lines, WM3211, 1205Lu, c83-2C, A375, SK-MEL-28, or SK-MEL-5, were cultured in RPMI 1640, L15/MCDB, F10, DMEM, EMEM, or AMEM media, respectively. MDA-MB-231, a breast cancer cell line, was grown in DMEM. Each medium was supplemented with 5% FBS, 5% neonatal bovine serum, and 2% penicillin (100 U/ml)/streptomycin (0.1 mg/ml). All cells were kept at 371C in 5% CO 2 incubator.
Cell cycle analysis using flow cytometry Cells were seeded in 100 mm tissue culture dishes (6 Â 10 5 cells/dish) (Corning Incorporated, Lowell, Massachusetts, USA) and grown overnight before drug treatment. For cell cycle analysis, WM3211, 1205Lu, and SK-MEL-28 cells were treated with various concentrations of PHA-739358 as indicated in the figure legends for 72 h. The drug-treated cells and untreated control samples were harvested by trypsinization and stained with propidium iodide (Sigma-Aldrich) in a modified Krishan buffer for 1 h at 41C. The propidium iodidestained samples were analyzed with a FACSCalibur Flow Cytometer (BD Immunocytometry Systems, San Jose, California, USA). Histograms were analyzed for cell cycle compartments, and the percentage of cells at each phase of the cell cycle was calculated using CellQuest Software (BD Immunocytometry Systems).
Sulforhodamine B cell viability assay treatment, cells were fixed with 10% trichloroacetic acid solution, and then were stained with 0.04% SRB. After washing with 1% acetic acid, SRB dye was dissolved with 50mmol/l Tris-base. Plates were finally read at optical density 564 nm using a Bio-Rad Model 680 Microplate Reader. Cell viability was calculated by dividing the average of the reading number for vehicle-treated control wells. The dose-response curves were plotted and the IC 50 values (concentration required to achieve 50% growth inhibition) were determined using the Prism 4 software (GraphPad Software Inc., La Jolla, California, USA).
Caspase 3/7 activity-based apoptosis assay Cells were seeded in a six-well plate (2 Â 10 5 cells/well) and incubated for 24 h at 371C to allow attachment. Cells were then treated with various concentrations of drugs as indicated in the figure legends for different cell lines. After washing with PBS solution, the cells were detached by trypsinization and combined with the culture media for each sample. The cell suspension was pelleted by centrifugation at 1000 rpm for 5 min. Cell lysis buffer (150 ml) (Cell Signaling Technology, Danvers, Massachusetts, USA) was added into the cell pellet and mixed by pipetting and incubated on ice for at least 30 min. The lysed cell mixture was spun down at 13 200g for 15 min to remove cell debris. Protein concentrations were determined using the BCA protein assay kit (Thermo Scientific, Rockford, Michigan). Caspase 3/7 activity was measured using the Caspase-Glo 3/7 Assay kit (Promega, Madison, Wisconsin, USA) according to the manufacturer instructions. Briefly, an equal volume (50 ml) of Caspase-Glo 3/7 reagent was added to each cell lysate sample (50 ml) in a Half Area 96-well assay plate (Corning Incorporated, Corning, New York, USA) with a final assay volume of 100 ml. Samples were incubated at room temperature for 1 h (protected from light) with shaking, and the luminescence of each sample is measured using a Combination-Modulus (Turner Biosystems, Sunnyvale, California, USA). The Caspase 3/7 activity was normalized to the amount of total protein contained in the cell lysate as determined by the BCA protein assay (Thermo Scientific).
In-vitro migration assay
The migration ability of the cells with or without treatment was tested using BD BioCoat Tumor Invasion Assay System (BD Biosciences, Bedford, Massachusetts, USA) according to the manufacturer's protocol. Briefly, cells were treated with various concentrations of PHA-739358 as indicated in the figure legends. After drug treatment, viable cells from each treatment group (75 000 cells/500 ml of serum free media (SFM), confirmed by trypan blue staining) were seeded onto the upper chamber, while medium containing 0.5-1% FBS (determined by cell type) was added into the lower compartment as a chemoattractant. After overnight incubation in a 5% CO 2 humidified incubator at 371C for 24 h, the cells on the upper chamber were carefully removed with a cotton swab and the cells that had traversed to reverse face of the membrane were fixed with methanol for 20 min, and stained with hematoxylin for 10 min. Photographs were taken and the number of cells on the reverse side of the filters were quantified by a Celestron 1600X LCD Deluxe Digital Microscope (Celestron LLC, Torrance, California, USA).
siRNA transfection SK-Mel-28 cells were seeded in 100-mm tissue culture dishes (6 Â 10 5 cells/dish) (Corning Incorporated, Lowell, Massachusetts, USA) 24 h before transfection. NFkB-P65 siRNA (100 nmol/l) (Hs_RELA_5 siRNA; Qiagen) was transfected into SK-Mel-28 melanoma cells with siLentFect transfection reagent (Bio-Rad). Cell lysates were harvested at 24 h after transfection to perform western blot analysis to determine the levels of NFkB-P65 and matrix metalloproteinase-2 (MMP-2).
Western blotting analysis
Cell lysates containing equal amount of protein (40 mg) were loaded on 10% SDS-PAGE gels. The separated proteins were transferred to polyvinylidene fluoride membranes. Membranes were then probed with primary antibodies against Aurora kinase A (AURKA) (GeneTex, Irvine, California, USA), Phospho-AURKA (Thr 288 ), Aurora kinase B (AURKB), Phospho-Histone H3 (Ser 10 ), MMP-2, Phospho-IkBa, Phospho-NFkB-p65, and b-actin (all from Cell Signaling Technology Inc.). b-Actin was included to serve as an internal control. The bound primary antibodies were detected using peroxidase-conjugated secondary antibodies (Cell Signaling Technology) and chemiluminescence by the Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, Massachusetts, USA) according to the manufacturer's instructions. The luminescent signal of the membrane was then detected by photographic film.
Results
Overexpression of Aurora kinases A and B in melanoma
It has been shown that both AURKA and AURKB levels are elevated in melanoma and increasing expression levels correspond to the progression of melanoma, from in situ to primary and metastatic melanoma [10] . Our analysis of gene expression microarray profiling data sets of normal skin, benign nevi, and cutaneous melanoma human tissues deposited in the oncomine database (http:// www.oncomine.com) also showed overexpression of both AURKA (P < 0.001) and AURKB (P < 0.00001) in melanoma tumor tissues in comparison to normal skin or benign nevi (Fig. 1a and b) . No difference was observed between melanoma tumor tissues and normal skin or benign nevi for AURKC (P = 0.3) (Fig. 1c) . Consistent with these findings, western blotting analysis demonstrated increased levels of AURKA and AURKB in all six melanoma cell lines tested, including WM3211, A375, 1205Lu, SK-MEL-5, C82-2C, SK-MEL-28, in comparison to normal human melanocytes (Fig. 1d) . MDA-MB-231 was used as a positive control for both AURKA and AURKB (Fig. 1d) .
PHA-739358 inhibits activities of Aurora kinases A and B in melanoma cells
Aurora kinases are key regulators of mitosis and deregulation of this activity can result in aneuploidy and carcinogenesis [20] , making them attractive targets for anticancer therapy [21, 22] . Several small molecule inhibitors of Aurora kinases with various properties are in clinical trials including PHA-739358 [17, 23] , MLN8054 [24] , and AZD1152 [25] . PHA-739358 is a pan-AKI with activity against all Aurora kinase family members (A, B, and C) [15, 26] . In this study, we examined whether PHA-739358 inhibits the activation and function of Aurora kinases A and B in melanoma cells in vitro.
SK-Mel-28 melanoma cells were treated with PHA-739358. Seventy-two hours after treatment, cell lysates were collected for western blot analysis to determine the phosphorylation of AURKA at threonine 288 (pThr288) and phosphorylation of Histone H3 at Serine 10 (pSer10).
Decreased phospho-AURKA and phospho-Histone H3 was evident in PHA-739358-treated SK-Mel-28 melanoma cells (Fig. 1e and f) .
Effects of PHA-739358 on cell viability of melanoma cell lines and immortalized human melanocytes WM3211, 1205Lu, SK-MEL-28, or A375 melanoma cells were treated with serial dilutions of PHA-739358. SRB cell viability assay was performed at 24, 48, or 72 h after drug treatment. The results demonstrated a dosedependent and time-dependent decrease of cell viability upon PHA-739358 treatment (Fig. 2a-d) , with low IC 50 s against WM3211 (1.76±0.04 mmol/l) (Fig. 2a) and 1205Lu (3.34±0.05 mmol/l) (Fig. 2b) cell lines, and a relatively higher IC 50 against A375 (6.00±0.13 mmol/l) (Fig. 2d) and SK-MEL-28 (12.45±0.27 mmol/l) (Fig. 2c ) cell lines after 72 h of drug treatment. To see whether PHA-739358 is toxic to normal melanocytes, we used two immortalized melanocyte cell lines PIG1 (provided by Dr Le Poole) and Mel-ST (provided by Dr Weinberg) to perform an in-vitro drugdose-response study. The results showed an IC 50 of 9.55±0.14 mmol/l for PIG1 cells (Fig. 2e) and 16 .00±0.34 mmol/l for Mel-ST cells (Fig. 2f) after 72-h drug treatment. 
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Effect of PHA-739358 on cell cycle progression in melanoma cell lines Propidium iodide staining combined with FACScan flow cytometry analysis was performed to investigate the effect of PHA-739358 on cell cycle progression in three melanoma cell lines (WM3211, 1205Lu, and SK-MEL-28). The results shown in Fig. 3a -j indicate that PHA-739358-treated cells resulted in an increased G2/M-phase population in all three cell lines in comparison to untreated control cells (two-fold induction at 1 mmol/l and three-fold induction at 5 mmol/l were observed in WM3211 cell line; seven-fold induction was observed at both 1 or 5 mmol/l treatment in 1205Lu cell line; three-fold induction at 5 mmol/l and two-fold induction at 10 mmol/l were observed in SK-MEL-28 cell line) (Fig. 3j) . A dramatically increased polyploidy population was observed in WM3211 (1.9-3.0-fold) and 1205Lu (1.5-1.9-fold) cell lines; only a slight induction (from 10.76 to 14.03% at 5 mmol/l) was observed in SK-MEL-28 cell line (Fig. 3j) . The data also demonstrated increased SubG1-phase population (Debris) upon PHA-739358 treatment in both WM3211 (4.8-fold at 1 mmol/l and 3.9-fold at 5 mmol/l) and SK-MEL-28 (1.7-fold at 5 mmol/l and 2.3-fold at 10 mmol/l) cell lines, and a 1.2-fold induction (from 6.86 to 8.43%) in 1205Lu at 5 mmol/l of PHA-739358 treatment (Fig. 3j) .
PHA-739358-induced apoptotic effect can be further enhanced by the addition of TMZ or Plx4032
Melanoma cells were treated with various concentrations of PHA-739358 as indicated in the figures (for WM3211 and 1205Lu cell lines with a range of 0-3 mmol/l; for SK-Mel-28 cells with a range of 0-10 mmol/l). Cell lysates were collected at 72 h after drug treatment. Caspase 3/7 activity assays indicated that PHA-739358 treatment resulted in a dose-dependent increase of caspase 3/7 activity in all three cell lines, including WM3211, 1205Lu, and SK-MEL-28 ( Fig. 4a-c) . Western blot analysis was performed using cell lysates collected from SK-Mel-28 cells with/without PHA-739358 exposure to measure the level of cleaved poly (ADP-ribose) polymerase (PARP). The results indicate an increased level of cleaved PARP upon PHA-739358 treatment of SK-Mel-28 cells (Fig. 4d) .
As SK-MEL-28 is the most resistant cell line (IC 50 = 12.45±0.27 mmol/l) (Fig. 2c) , we investigated whether addition of PHA-739358 could sensitize SK-MEL-28 cells to TMZ treatment. SK-MEL-28 cells were treated with 0, 5, or 10 mmol/l of PHA-739358 with or without 200 mmol/l of TMZ treatment. Caspase activity assay was performed at 72 h after drug treatment. From Fig. 5a we can see that, 
Effect of PHA-739358 on cell cycle progression in melanoma cell lines. WM3211 (a-c), 1205Lu (d-f), and SK-MEL-28 (g-i) cells were treated with various concentrations of PHA-739358 as indicated in the figures. After 72 h of drug treatment, flow cytometry analysis of cell cycle was performed using propidium iodide staining. Histograms were analyzed for cell cycle compartments, and the percentage of cells at each phase of the cell cycle was calculated using CellQuest Pro Software (BD Immunocytometry Systems) (a-j).
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TMZ alone slightly decreased caspase activity in comparison to untreated control; however, when combined with 5 mmol/l of PHA-739358, the caspase activity was significantly enhanced over either drug alone. Increased caspase activity and PARP cleavage were also observed when TMZ was added to 10 mmol/l of PHA-739358 in comparison to either TMZ or PHA alone ( Fig. 5a and b) . Activating BRAF (V600E) mutations occur in B60% of melanomas. Early clinical experience with a novel class I RAF-selective inhibitor, Plx4032, demonstrated an unprecedented 80% antitumor response rate among patients with BRAF(V600E)-positive melanomas, but acquired drug resistance frequently develops after initial responses. Aurora B is a downstream target of mitogen-activated protein kinase signaling that is reactivated in Plx4032-resistant melanoma cells, making it an attractive therapeutic target for Plx4032-resistant patients. In this study, we also showed that PHA treatment significantly enhanced Plx4032-induced caspase activation and PARP cleavage ( Fig. 5c and d) .
Dose-dependent cell migration inhibition upon PHA-739358 treatment in melanoma cell lines
Recently it has been shown that upregulation of Aurora A mRNA and protein level was significantly correlated with the occurrence of regional lymph node and distant metastasis in head and neck squamous cell carcinoma [27] . Another study by Wan et al. [28] showed Aurora A was involved in epithelial mesenchymal transition and invasion in nasopharyngeal carcinoma. Melanoma is a highly metastatic tumor. Metastasis to the central nervous system occurs in over 50% of patients with advanced melanoma. Furthermore, mortality from melanoma metastasizing to the central nervous system or brain is particularly high, with a median overall survival of 4.4 months and a 5-year survival rate of 3% [29] . However, whether the pan-AKI PHA-739358 could prevent melanoma cell migration had not been characterized. To test the migration inhibition potential of PHA-739358, SK-MEL-28, and 1205Lu melanoma cells were treated with increasing concentration of PHA-739358 for 72 h as indicated in Fig. 6a and b, respectively. Representative images of SK-MEL-28 cells after 72 h PHA-739358 treatment are shown in Supplemental Fig. 1(a-c) . Surviving cells were equally (75 000 cells/500 ml of SFM, confirmed by trypan blue staining) seeded into BioCoat chamber as described in the Materials and methods section and incubated for 24 h at 371C. Supplemental Fig. 3 shows representative photographs of SK-MEL-28 A(a-c) and 1205Lu cells B(d-f) migrating (Fig. 5a) ; 66% inhibition at 0.1 mmol/l and 100% inhibition at 3 mmol/l in 1205Lu cell line (Fig. 5b) ]. Next, a wound closure assay was performed with SK-MEL-28 cells and the results showed that PHA-739358 (100 nmol/l) significantly reduced cell migration (Supplemental Fig. 3 ). The quantified results showed a 70, 90, and 99% migration inhibition after 24, 48, or 72 h PHA-739358 treatments, respectively, in comparison to control group (Fig. 6c) .
Inhibition of NFjB-signaling pathway may be involved in PHA-739358-induced MMP-2 downregulation
MMPs are a family of proteinases with various substrates and functions, including angiogenesis, tissue invasion, inflammation, and tumor metastasis [30, 31] . In melanoma, both MMP-2 and MMP-9 were involved in cell invasion [32, 33] ; however, only MMP-2 overexpression was correlated with progression and survival [34] [35] [36] [37] . Here, we investigated whether MMP-2 was involved in PHA-739358-induced migration inhibition in melanoma cell lines. SK-MEL-28 cells were treated with PHA-739358 (0, 0.1, 5, 10 mmol/l) for 72 h, and then subjected to immunobloting . For the PHA-739358 and Plx4032 combination, cells were treated with Plx4032 (10 mmol/l) for 24 h, and then fresh media were changed and followed by PHA-739358 treatment (10 mmol/l) for 48 h. Cell lysates were then collected for caspase activity evaluation using Caspase 3/7 Glow Assay or cleaved PARP detection using western blot (c, d). *P < 0.05, **P < 0.0001 when means from PHA-739358 plus TMZ-treated samples are compared with either TMZ or PHA-739358 alone. PARP, poly (ADP-ribose) polymerase; TMZ, temozolomide.
analysis for MMP-2. As shown in Fig. 7a and b, PHA-739358 treatment leads to reduced protein expression of MMP-2 in a dose-dependent manner. Membranes were stripped and reprobed with anti-Phospho-IkBa and anti-PhosphoNFkB-p65 antibodies to evaluate the effect of PHA-739358 on the activities of NFkB-signaling pathway. Decreased Phospho-IkBa and Phospho-NFkB-p65 expression was observed after PHA-739358 treatment indicating reduced activity in the NFkB-signaling pathway ( Fig. 7a  and b) . Consistent with the literature [38] , inhibition of NFkB using MG132 (a protease inhibitor that can inhibit NFkB activity) resulted in decreased MMP-2 expression in SK-MEL-28 cell line ( Fig. 7c and d) . Furthermore, siRNA knockdown of NFkB-P65 resulted in decreased MMP-2 expression as well ( Fig. 7e and f) .
Discussion
Overexpression of Aurora kinases has been shown in many tumors. Thus, the inhibition of Aurora kinases has moved into the anticancer therapy arena. Several AKIs have been tested in melanoma preclinically in the last few years [10] [11] [12] , indicating that Aurora kinases are potential therapeutic targets. In the current study, we investigated the antiproliferative and anti-invasive effects of PHA-739358 (one of the most clinically advanced compounds that have been entered into phase II clinical trials) on melanoma cells. To the best of our knowledge, this is the first study to show the antiproliferative and anti-invasive effects of PHA-739358 in melanoma in vitro.
To assess the impact of Aurora kinases as a potential molecular target in melanoma, we first screened the oncomine DNA microarray database (http://www.oncomine. com). The results demonstrated increased mRNA levels for both AURKA (P < 0.001) and AURKB (P < 0.00001) in melanoma tissues in comparison to normal skin or benign nevi from the data set deposited by Haqq et al. [39] through oncomine, which is also consistent with the data published by Wang et al. [10] . Overexpression of Aurora kinases A and B were also detected in melanoma cell lines (Fig. 1d ). All these lines of evidence indicate that Aurora kinases A and B are overexpressed in melanoma tumor tissue and cell lines, making them ideal targets for therapeutic intervention.
Many AKIs have been discovered, and are currently under preclinical or clinical development. PHA-739358 is among the few AKIs that have entered phase II clinical trials for patients with solid tumors (http://www.clinicaltrials.gov). PHA-739358 is a small ATP competitive molecule that inhibits Aurora A, B, and C kinases [16] . PHA-739358 has strong activity on Aurora A, as determined by inhibition of autophosphorylation in position Thr288 [40] and also on Aurora B as determined by inhibition of its substrate histone H3 in position Ser10 [41] . Using SK-MEL-28 melanoma cells as an example, inhibition for both AURKA and AURKB activities was seen from 0.1 mmol/l concentrations upward ( Fig. 1e and f) .
In-vitro studies have shown that PHA-739358 causes a failure of cell division, resulting in polyploidy and reduction in viability in hepatocellular carcinoma and pancreatic cancer cells [19, 42] . In this study, we also showed increased G2/M arrest and polyploidy and inhibited cell proliferation upon PHA-739358 treatment in melanoma cell lines. Increased caspase activation and PARP cleavage were also observed upon PHA-739358 exposure. Additionally, PHA-739358 enhanced TMZ and Plx4032-induced apoptotic effect. Cotreatment of PHA-739358 and Plx4032 does not have a synergistic effect on cell proliferation inhibition (data not shown); however, the Plx4032-induced apoptotic effect was enhanced when followed by PHA-739358 treatment (Fig. 5) , indicating that PHA-739358 could serve as a second-line therapy and provides rationales for future clinical trials using PHA-739358 in this tumor entity.
Several lines of evidence have shown that Aurora A kinase is involved in progression of cancer metastasis [27, 28, 43] , which is a crucial feature of malignant melanoma [44] . This study provides the first evidence for the antimetastatic effect of PHA-739358 in melanoma in vitro. Overexpression of MMPs is a key factor for tumor invasion and metastasis [45] , and MMP-2 overexpression is closely correlated to melanoma progression and survival [37] . In the current study, we have shown that PHA-739358- induced MMP-2 downregulation by inhibition of the NFkB-signaling pathway.
Conclusion
Our results provide the first evidence for the antiproliferative and antimetastatic effects of the pan-AKI, PHA-739358, on melanoma cell lines. Targeted inhibition of Aurora kinases by PHA-739358, alone or in combination, may offer a promising new approach for the treatment of patients with advanced stage melanoma. In addition, the increased efficacy of the AKI secondary to Plx4032 failure [13] raises expectations for an effective secondline therapy and provides further rational for future clinical trials using PHA-739358 in melanoma. In summary, our study provides a solid foundation for further in-vivo or even clinical evaluation of the antitumor and antimetastatic effects of PHA-739358 alone or in combination against melanoma.
